John Wiley & Sons : Study Provides Insights on Statins’ Link to Lower Prostate Cancer Risk
October 09, 2019 at 12:56 am EDT
Share
In a study of cancer‐free men followed for a median of seven years, statin use was associated with a lower risk of developing prostate cancer. In the Cancer Medicine study, this association was observed only when statins had been used for a relatively long duration or at a high dose, and it was more pronounced for aggressive prostate tumors.
Among 13,065 men in the study, 2,976 were diagnosed with prostate cancer over a follow-up of up to 22 years.
'More strictly designed clinical trial studies are needed to replicate this finding,' said Kai Wang, first author, PhD, of Harvard University.
Additional Information
Link to Study: https://onlinelibrary.wiley.com/doi/10.1002/cam4.2500
About Journal
Cancer Medicine is a peer-reviewed, open access, interdisciplinary journal providing rapid publication of research from global biomedical researchers across the cancer sciences. The journal will consider submissions from all oncologic specialties, including, but not limited to, the following areas:
Cancer Biology
Molecular biology ∙ cellular biology ∙ molecular genetics ∙ genomics ∙ immunology ∙ epigenetics ∙ metabolic studies ∙ proteomics ∙ cytopathology ∙ carcinogenesis ∙ drug discovery and delivery
Clinical Cancer Research
Translational research ∙ clinical trials ∙ chemotherapy ∙ radiation therapy ∙ surgical therapy ∙ clinical observations ∙ clinical guidelines ∙ genetic consultation ∙ ethical considerations
Cancer Prevention
Behavioral science ∙ psychosocial studies ∙ screening ∙ nutrition ∙ epidemiology and prevention ∙ community outreach
About Wiley
Wiley drives the world forward with research and education. Through publishing, platforms and services, we help students, researchers, universities, and corporations to achieve their goals in an ever-changing world. For more than 200 years, we have delivered consistent performance to all of our stakeholders. The Company's website can be accessed at www.wiley.com.
Attachments
Original document
Permalink
Disclaimer
John Wiley & Sons Inc. published this content on 09 October 2019 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 09 October 2019 04:55:10 UTC
John Wiley & Sons, Inc. is a knowledge company. The Company is engaged in providing research, publishing, and knowledge solutions. The Company's segments include Research, Learning, and Held for Sale or Sold. Research segment is a provide peer-reviewed scientific, technical, and medical (STM) publishing, content platforms, and related services to academic, corporate, and government customers, academic societies, and individual researchers. The Learning segment provides scientific, professional, and education print and digital books, digital courseware to libraries, corporations, students, professionals, and researchers, as well as assessment services to businesses and professionals. The Company's Research Publishing products provide scientific, technical, medical, and scholarly journals, as well as related content and services, to academic, corporate, and government libraries, learned societies, and individual researchers, and other professionals.